Political pressure is weighing on drug and medical device stocks including Abbott Labs (ABT) and St. Jude (STJ) , says TheStreet's Jim Cramer. St. Jude posted lower-than-expected earnings for the 2016 third quarter. Before today's opening bell, the Saint Paul, MN-based medical device company reported adjusted earnings of $0.99 a share, missing analysts' estimates for adjusted earnings of $1.01 a share. Revenue climbed 12% year-over-year to $1.5 billion and largely met Wall Street's expectations. The company withdrew its guidance for 2016 due to its $25 billion planned sale to Abbott Laboratories. The deal is expected to close in the 2016 fourth quarter.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.